Introduction: Fibromyalgia from the perspective of neuropathic pain

Journal of Rheumatology

Volumn 32, Issue SUPPL. 75, 2005, Pages 1-5

  Dworkin, Robert H ^a,c   Fields, Howard L ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; DULOXETINE; GABAPENTIN; LIDOCAINE; NORADRENALIN UPTAKE INHIBITOR; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CHRONIC PAIN; CONFERENCE PAPER; FIBROMYALGIA; HUMAN; INTERNATIONAL COOPERATION; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 23444448624     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Merskey H, Bogduk N, editors. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle: IASP Press; 1994.
2. Max MB. Clarifying the definition of neuropathic pain. Pain 2002;96:406-7.
3. Hansson PT, Fields HL, Hill RG, Marchettini P, editors. Neuropathic pain: pathophysiology and treatment. Seattle: IASP Press; 2001.
4. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001;134:868-81.
5. Woolf CJ, Max MB. Mechanism-based pain diagnosis. Anesthesiology 2001;95:241-9.
6. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-51.
7. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998;5:209-27.
8. Rowbotham MC, Baron R, Petersen KL, Fields HL. Spectrum of pain mechanisms contributing to PHN. In: Watson CPN, Gershon AA, editors. Herpes zoster and postherpetic neuralgia. 2nd ed. New York: Elsevier Press; 2001:39-64.
9. Petersen KL, Fields HL, Brennum J, Sandroni P, Rowbotham MC. Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain 2000;88:125-33.
10. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003;102:1-8.
11. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997;48:332-8.
12. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004;108:248-57.
13. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-34.
14. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004;63:959-65.
15. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;100:697-706.
16. Goldstein DJ, Pritchett YL, Detke MJ, Lee TC, Lyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005 May 28;[Epub ahead of print].
17. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
18. Turk DC. The potential of treatment matching for subgroups of patients with chronic pain: lumping versus splitting. Clin J Pain 2005;21:44-55.
19. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59:1015-21.
20. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003;36:877-82.
21. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 95;I22:561-8.
22. Fassoulaki A, Patris K, Sarantopoulos C, Hogan Q. The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth Analg 2002;95:985-91.
23. Fassoulaki A, Sarantopoulos C, Melemeni A, Hogan Q. EMLA reduces acute and chronic pain after breast surgery for cancer. Reg Anesth Pain Med 2000;25:350-5.
24. Reuben SS, Makari-Judson G, Lurie SD. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J Pain Symptom Manage 2004;27:133-9.
25. Bennett R. Fibromyalgia: present to future. Curr Pain Headache Rep 2004;8:379-84.
26. Staud R. Fibromyalgia: do we know the source? Curr Opin Rheumatol 2004;16:157-63.
27. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-45.
28. Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain 2004;110:449-60.
29. Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution of central sensitization to the development of noncardiac chest pain. Lancet 2000;356:1154-9.
30. Okifuji A, Turk DC, Marcus DA. Comparison of generalized and localized hyperalgesia in patients with recurrent headache and fibromyalgia. Psychosom Med 1999;61:771-80.
31. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005;114:295-302.
32. Turk DC, Okifuji A, Sinclair JD, Starz TW. Differential responses by psychosocial subgroups of fibromyalgia syndrome patients to an interdisciplinary treatment. Arthritis Care Res 1998;11:397-404.
33. Barkhuizen A. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 2002;28:261-90.
34. Rao SG, Bennett RM. Pharmacologic therapies in fibromyalgia. Best Pract Res Clin Rheumatol 2003;17:611-27.
35. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95.
36. Holroyd KA, O'Donnell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson BW. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA 2001;285:2208-15.
37. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003;60:1284-9.
38. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002;6:17-24.
39. Spath M. Current experience with 5-HT3 receptor antagonists in fibromyalgia. Rheum Dis Clin North Am 2002;28:319-28.
40. Farber L, Stratz TH, Brückle W, et al. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron: results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients. Int J Clin Pharm Res 2001;21:1-13.
41. Spath M, Stratz T, Neeck G, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004;33:267-70.
42. Turk DC, Okifuji A, Starz TW, Sinclair JD. Effects of type of symptom onset on psychological distress and disability in fibromyalgia syndrome patients. Pain 1996;68:423-30.
43. Simms RW, Felson DT, Goldenberg DL. Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol 1991;18:1558-63.
44. Ortiz Z, Shea B, Garcia Dieguez M, et al. The responsiveness of generic quality of life instruments in rheumatic diseases: a systematic review of randomized controlled trials. J Rheumatol 1999;26:210-6.
45. Dunkl PR, Taylor AG, McConnell GG, Alfano AP, Conaway MR. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000;27:2683-91.